Inequities in Antiviral Therapy for Diabetic Individuals Affected by COVID-19

Abstract

Diabetes patients are more vulnerable to COVID-19 infections, which can cause serious respiratory conditions. In this study, the effect of the antiviral medication with molnupiravir and favipiravir was compared in COVID-19 patients with underlying diabetes. The current investigation included a cohort of 100 people who had been diagnosed with diabetes, had a SARS-CoV-2 infection, and had been admitted sequentially. The antiviral drugs were administered to these patients according to regional reco